- Home
- REBN vs BDRX Comparison
REBN vs BDRX Comparison
Compare REBN & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- BDRX
- Stock Information
- Founded
- REBN 2015
- BDRX 2000
- Country
- REBN United States
- BDRX United Kingdom
- Employees
- REBN N/A
- BDRX N/A
- Industry
- REBN Restaurants
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- BDRX Health Care
- Exchange
- REBN Nasdaq
- BDRX Nasdaq
- Market Cap
- REBN 12.8M
- BDRX 5.8M
- IPO Year
- REBN 2022
- BDRX N/A
- Fundamental
- Price
- REBN $2.94
- BDRX $0.88
- Analyst Decision
- REBN
- BDRX
- Analyst Count
- REBN 0
- BDRX 0
- Target Price
- REBN N/A
- BDRX N/A
- AVG Volume (30 Days)
- REBN 63.3K
- BDRX 4.2M
- Earning Date
- REBN 08-18-2025
- BDRX 04-11-2025
- Dividend Yield
- REBN N/A
- BDRX N/A
- EPS Growth
- REBN N/A
- BDRX N/A
- EPS
- REBN N/A
- BDRX N/A
- Revenue
- REBN $6,103,732.00
- BDRX N/A
- Revenue This Year
- REBN $335.98
- BDRX N/A
- Revenue Next Year
- REBN N/A
- BDRX N/A
- P/E Ratio
- REBN N/A
- BDRX N/A
- Revenue Growth
- REBN 3.38
- BDRX N/A
- 52 Week Low
- REBN $1.03
- BDRX $0.78
- 52 Week High
- REBN $8.30
- BDRX $30.00
- Technical
- Relative Strength Index (RSI)
- REBN 58.68
- BDRX 42.16
- Support Level
- REBN $2.70
- BDRX $0.82
- Resistance Level
- REBN $3.16
- BDRX $1.33
- Average True Range (ATR)
- REBN 0.21
- BDRX 0.09
- MACD
- REBN 0.04
- BDRX 0.02
- Stochastic Oscillator
- REBN 73.77
- BDRX 11.75
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.